In 2003, Al-Hajj et al. published a groundbreaking work that breast cancer cells bearing the phenotype of CD44+/CD24− had enriched CSC properties, which set the foundation for studying CSCs in breast cancer and other solid tumors [18]. The gene discussed is CD44; the disease is breast cancer.